Home / Business and Economy / Eli Lilly Stock: Undervalued or Overhyped?
Eli Lilly Stock: Undervalued or Overhyped?
5 Aug
Summary
- FDA Breakthrough Therapy designation for pancreatic cancer drug.
- Stock shows recent pullback despite strong long-term returns.
- Valuation suggests significant undervaluation based on growth.
Eli Lilly (LLY) is gaining attention following the FDA's Breakthrough Therapy designation for its investigational drug, olomorasib, targeting KRAS G12C-mutant advanced pancreatic cancer. This development underscores the company's growing focus on oncology.
Despite a recent 7-day share price decline of 8.60% and an 8.09% drop over 30 days, Eli Lilly's 1-year total shareholder return stands at 46.69%, with a remarkable 334.06% over five years. The company's strong performance in obesity and diabetes treatments continues, complemented by recent progress in oncology.
Current valuations suggest Eli Lilly's stock is significantly undervalued. One narrative places its fair value at $1,477.03, a considerable increase from its last close of $1,115.68. This valuation anticipates continued growth in obesity and diabetes earnings, potential profitability at scale, and future earnings multiples.
However, potential risks include intensifying pricing pressure in obesity treatments and disappointing late-stage trial data for new drugs. These factors could alter the company's trajectory.
